Glenmark Life Sciences Limited

NSEI:GLS Stock Report

Market Cap: ₹103.9b

Glenmark Life Sciences Valuation

Is GLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GLS (₹848.3) is trading above our estimate of fair value (₹364.52)

Significantly Below Fair Value: GLS is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GLS?

Other financial metrics that can be useful for relative valuation.

GLS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.4x
Enterprise Value/EBITDA15x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does GLS's PE Ratio compare to its peers?

The above table shows the PE ratio for GLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average89x
530019 Jubilant Pharmova
148.9xn/a₹114.8b
AETHER Aether Industries
142.4x40.9%₹117.5b
500126 Procter & Gamble Health
39.5xn/a₹84.6b
524742 Caplin Point Laboratories
25.2x11.7%₹115.3b
GLS Glenmark Life Sciences
22.1x13.0%₹103.9b

Price-To-Earnings vs Peers: GLS is good value based on its Price-To-Earnings Ratio (22.1x) compared to the peer average (89x).


Price to Earnings Ratio vs Industry

How does GLS's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: GLS is good value based on its Price-To-Earnings Ratio (22.1x) compared to the Indian Pharmaceuticals industry average (35x).


Price to Earnings Ratio vs Fair Ratio

What is GLS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GLS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.1x
Fair PE Ratio30.1x

Price-To-Earnings vs Fair Ratio: GLS is good value based on its Price-To-Earnings Ratio (22.1x) compared to the estimated Fair Price-To-Earnings Ratio (30.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GLS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹848.30
₹932.60
+9.9%
9.2%₹1,040.00₹790.00n/a5
Jul ’25₹887.40
₹932.60
+5.1%
9.2%₹1,040.00₹790.00n/a5
Jun ’25₹836.25
₹932.60
+11.5%
9.2%₹1,040.00₹790.00n/a5
May ’25₹828.90
₹932.60
+12.5%
9.2%₹1,040.00₹790.00n/a5
Apr ’25₹785.05
₹874.67
+11.4%
8.9%₹940.00₹765.00n/a3
Mar ’25₹859.60
₹874.67
+1.8%
8.9%₹940.00₹765.00n/a3
Feb ’25₹856.70
₹874.67
+2.1%
8.9%₹940.00₹765.00n/a3
Jan ’25₹655.20
₹685.00
+4.5%
6.7%₹720.00₹620.00n/a3
Dec ’24₹636.90
₹685.00
+7.6%
6.7%₹720.00₹620.00n/a3
Nov ’24₹619.45
₹685.00
+10.6%
6.7%₹720.00₹620.00n/a3
Oct ’24₹617.95
₹707.75
+14.5%
7.5%₹756.00₹620.00n/a4
Sep ’24₹631.80
₹708.20
+12.1%
6.7%₹756.00₹620.00n/a5
Aug ’24₹639.90
₹708.20
+10.7%
6.7%₹756.00₹620.00n/a5
Jul ’24₹569.15
₹603.00
+5.9%
8.9%₹685.00₹525.00₹887.405
Jun ’24₹542.90
₹603.00
+11.1%
8.9%₹685.00₹525.00₹836.255
May ’24₹504.30
₹586.80
+16.4%
6.0%₹630.00₹525.00₹828.905
Apr ’24₹392.90
₹551.00
+40.2%
8.5%₹604.00₹485.00₹785.054
Mar ’24₹374.90
₹551.00
+47.0%
8.5%₹604.00₹485.00₹859.604
Feb ’24₹380.10
₹551.00
+45.0%
8.5%₹604.00₹485.00₹856.704
Jan ’24₹420.15
₹562.25
+33.8%
7.2%₹629.00₹525.00₹655.204
Dec ’23₹433.30
₹562.25
+29.8%
7.2%₹629.00₹525.00₹636.904
Nov ’23₹437.20
₹562.25
+28.6%
7.2%₹629.00₹525.00₹619.454
Oct ’23₹385.80
₹624.75
+61.9%
7.2%₹684.00₹560.00₹617.954
Sep ’23₹439.80
₹624.75
+42.1%
7.2%₹684.00₹560.00₹631.804
Aug ’23₹474.15
₹660.25
+39.2%
8.0%₹751.00₹620.00₹639.904
Jul ’23₹442.40
₹662.75
+49.8%
7.8%₹751.00₹620.00₹569.154

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.